General
Preferred name
Biguanide
Synonyms
Duraplus ()
Biguanide sulphate ()
P&D ID
PD058241
CAS
4911-98-2
56-03-1
6945-23-9
2583-53-1
Tags
available
drug
Drug Status
approved
investigational
Max Phase
3.0
Drug indication
diabetes mellitus
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Biguanide is an orally active antihyperglycemic agent. Biguanide inhibits mitochondrial ATP production, activates the LKB1-AMPK signaling pathway, and damages the energy homeostasis. Biguanide exhibits potential in ameliorating the type 2 diabetes and the insulin-associated cancers[1].
DESCRIPTION
Biguanide has been investigated for the treatment of Diabetes Mellitus.
(Enamine Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
5
ChEMBL Drugs
DrugBank
DrugBank Approved Drugs
Enamine Bioactive Compounds
MedChem Express Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
40
Molecular Weight
101.07
Hydrogen Bond Acceptors
2
Hydrogen Bond Donors
5
Rotatable Bonds
0
Ring Count
0
Aromatic Ring Count
0
cLogP
-1.64
TPSA
111.77
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
0.0
QED
0.19
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
AMPK
Insulin Receptor
Mitochondrial Metabolism
Pathway
Epigenetics
Metabolic Enzyme/Protease
PI3K/Akt/mTOR
Protein Tyrosine Kinase/RTK
Source data
